122 related articles for article (PubMed ID: 24676806)
21. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
23. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.
Wu J; Liu Z; Shao C; Gong Y; Hernando E; Lee P; Narita M; Muller W; Liu J; Wei JJ
Cancer Res; 2011 Jan; 71(2):349-59. PubMed ID: 21224353
[TBL] [Abstract][Full Text] [Related]
24. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
25. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids.
Conrad O; Burgy M; Foppolo S; Jehl A; Thiéry A; Guihard S; Vauchelles R; Jung AC; Mourtada J; Macabre C; Ledrappier S; Chenard MP; Onea MA; Danic A; Dourlhes T; Thibault C; Schultz P; Dontenwill M; Martin S
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446353
[TBL] [Abstract][Full Text] [Related]
27. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
28. The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: the underestimated driving force affecting prognosis.
Cuello MA; Kato S; Liberona F
J Cell Mol Med; 2018 Mar; 22(3):1805-1815. PubMed ID: 29266765
[TBL] [Abstract][Full Text] [Related]
29. Ascites-Derived Extracellular microRNAs as Potential Biomarkers for Ovarian Cancer.
Záveský L; Jandáková E; Weinberger V; Minář L; Hanzíková V; Dušková D; Drábková LZ; Svobodová I; Hořínek A
Reprod Sci; 2019 Apr; 26(4):510-522. PubMed ID: 29779470
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy.
Xia B; Hou Y; Chen H; Yang S; Liu T; Lin M; Lou G
Oncotarget; 2017 Mar; 8(12):19534-19546. PubMed ID: 28099946
[TBL] [Abstract][Full Text] [Related]
32. Screening of Critical Genes Involved in Metastasis and Prognosis of High-Grade Serous Ovarian Cancer by Gene Expression Profile Data.
Wang R; Du X; Zhi Y
J Comput Biol; 2020 Jul; 27(7):1104-1114. PubMed ID: 31725318
[TBL] [Abstract][Full Text] [Related]
33. Abnormal miRNA-30e Expression is Associated with Breast Cancer Progression.
Lin Z; Li JW; Wang Y; Chen T; Ren N; Yang L; Xu W; He H; Jiang Y; Chen X; Liu T; Liu G
Clin Lab; 2016; 62(1-2):121-8. PubMed ID: 27012041
[TBL] [Abstract][Full Text] [Related]
34. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
35. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
36. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.
Liu Z; Liu J; Segura MF; Shao C; Lee P; Gong Y; Hernando E; Wei JJ
J Pathol; 2012 Oct; 228(2):204-15. PubMed ID: 22322863
[TBL] [Abstract][Full Text] [Related]
37. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
38. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
39. miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.
Arts FA; Keogh L; Smyth P; O'Toole S; Ta R; Gleeson N; O'Leary JJ; Flavin R; Sheils O
Hum Pathol; 2017 Dec; 70():98-104. PubMed ID: 29079174
[TBL] [Abstract][Full Text] [Related]
40. Peritoneal papillary serous carcinoma: study of 15 cases and comparison with stage III-IV ovarian papillary serous carcinoma.
Piura B; Meirovitz M; Bartfeld M; Yanai-Inbar I; Cohen Y
J Surg Oncol; 1998 Jul; 68(3):173-8. PubMed ID: 9701210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
